The Next Generation

Thomas Rohrer at Lonza highlights the advantages of antibody drug conjugates, but cautions that these highly potent biopharmaceuticals present a series of unique manufacturing challenges due to their potency and the raw material supply chain.

Thomas Rohrer, Lonza (June 2013)

Keywords: Antibody drug conjugate (ADC) Monoclonal antibody (mAb) Cytotoxin Maximum acceptable carryover (MAC) calculation

View full article    |    Back to Manufacturing section